Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Inclusion Criteria:

1. Newly diagnosed previously untreated ALL or lymphoblastic lymphoma \>/= 18 years old. Allow urgent administration of cytarabine/hydrea/atra prior to starting treatment on protocol. Allow previous administration of up to one course of Hyper-CVAD and/or FDA approved TKI.
2. Zubrod performance status \</= 3.
3. Adequate liver function (bilirubin \</= 3.0 mg/dl unless considered due to tumor) and renal function (creatinine \</= 3.0 mg/dl, unless considered due to tumor).
4. No active co-existing malignancy with life expectancy less than 12 months due to that malignancy.
5. All men and women of childbearing potential who are participating in the study must agree to use effective forms of birth control throughout the duration of their treatment.
6. Adequate cardiac function as assessed clinically

Exclusion Criteria:

1. Pregnant or lactating women. Women of childbearing potential (WOCB) must have a blood or urine pregnancy test within 7 days prior to administration of the study drug. (WOCB is defined as a woman who has not undergone hysterectomy or bilateral oophorectomy and has not been naturally postmenopausal for at least 24 consecutive months).
2. Active Grade III-IV cardiac failure as defined by the New York Heart Association criteria, uncontrolled angina or MI within 6 months.
3. Patients with medical conditions that compromise their ability to complete the study or confound interpretation of study results.